<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Affect Disord</journal-id><journal-id journal-id-type="iso-abbrev">J Affect Disord</journal-id><journal-title-group><journal-title>Journal of Affective Disorders</journal-title></journal-title-group><issn pub-type="ppub">0165-0327</issn><issn pub-type="epub">1573-2517</issn><publisher><publisher-name>Elsevier/North-Holland Biomedical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24836086</article-id><article-id pub-id-type="pmc">4315809</article-id><article-id pub-id-type="publisher-id">S0165-0327(14)00171-2</article-id><article-id pub-id-type="doi">10.1016/j.jad.2014.03.051</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Report</subject></subj-group></article-categories><title-group><article-title>Are multiple physical symptoms a poor prognostic factor or just a marker of depression severity? Secondary analysis of the GenPod trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Green</surname><given-names>Amy</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">⁎</xref></contrib><contrib contrib-type="author"><name><surname>Crawford</surname><given-names>Andrew</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Button</surname><given-names>Katherine S.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Wiles</surname><given-names>Nicola</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Peters</surname><given-names>Tim J.</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Nutt</surname><given-names>David</given-names></name><xref rid="aff0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Lewis</surname><given-names>Glyn</given-names></name><xref rid="aff0020" ref-type="aff">d</xref></contrib></contrib-group><aff id="aff0005"><label>a</label>Centre for Academic Mental Health, School of Social and Community Medicine, University of Bristol, United Kingdom</aff><aff id="aff0010"><label>b</label>School of Clinical Sciences, University of Bristol, United Kingdom</aff><aff id="aff0015"><label>c</label>Faculty of Medicine, Department of Medicine, Imperial College London, United Kingdom</aff><aff id="aff0020"><label>d</label>Division of Psychaitry, Faculty of Brain Sciences, University College, London, United Kingdom</aff><author-notes><corresp id="cor1"><label>⁎</label>Corresponding author. Tel.: +44 117 3314007.</corresp></author-notes><pub-date pub-type="pmc-release"><day>1</day><month>7</month><year>2014</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2014</year></pub-date><volume>163</volume><fpage>40</fpage><lpage>46</lpage><history><date date-type="received"><day>28</day><month>11</month><year>2013</year></date><date date-type="rev-recd"><day>26</day><month>3</month><year>2014</year></date><date date-type="accepted"><day>27</day><month>3</month><year>2014</year></date></history><permissions><copyright-statement>© 2014 The Authors. Published by Elsevier B.V.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Elsevier B.V.</copyright-holder><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract><sec><title><offsets xml_i="3862" xml_f="3872" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3883" xml_f="4227" txt_i="22" txt_f="366">Using data from the GenPod trial this study investigates: (i) if depressed individuals with multiple physical symptoms have a poorer response to antidepressants before and after adjustment for baseline Beck Depression Inventory II (BDI-II); and (ii) if reboxetine is more effective than citalopram in depression with multiple physical symptoms.</offsets></p></sec><sec><title><offsets xml_i="4249" xml_f="4256" txt_i="368" txt_f="375">Methods</offsets></title><p><offsets xml_i="4267" xml_f="4365" txt_i="376" txt_f="474">Linear regression models were used to estimate differences in mean BDI-II score at 6 and 12 weeks.</offsets></p></sec><sec><title><offsets xml_i="4387" xml_f="4394" txt_i="476" txt_f="483">Results</offsets></title><p><offsets xml_i="4405" xml_f="4953" txt_i="484" txt_f="1032">Before adjusting for baseline BDI-II, the difference in mean BDI-II score between no and multiple physical symptoms was 4.5 (95% CI 1.87, 7.14) at 6 weeks, 4.51 (95% CI 1.60, 7.42) at 12 weeks. After adjustment for baseline BDI-II, there was no evidence of a difference in outcome according to physical symptoms with a difference in mean BDI-II of 2.17 (95% CI −0.39, 4.73) at 6 weeks and 2.43 (95% CI −0.46, 5.32) at 12 weeks. There was no evidence that reboxetine was more effective than citalopram in those with multiple physical symptoms at 6 (</offsets><italic><offsets xml_i="4961" xml_f="4963" txt_i="1032" txt_f="1034">P=</offsets></italic><offsets xml_i="4972" xml_f="4991" txt_i="1034" txt_f="1053">0.18) or 12 weeks (</offsets><italic><offsets xml_i="4999" xml_f="5001" txt_i="1053" txt_f="1055">P=</offsets></italic><offsets xml_i="5010" xml_f="5016" txt_i="1055" txt_f="1061">0.24).</offsets></p></sec><sec><title><offsets xml_i="5038" xml_f="5049" txt_i="1063" txt_f="1074">Limitations</offsets></title><p><offsets xml_i="5060" xml_f="5168" txt_i="1075" txt_f="1183">Differential non-adherence between treatment arms has the potential to bias estimates of treatment efficacy.</offsets></p></sec><sec><title><offsets xml_i="5190" xml_f="5200" txt_i="1185" txt_f="1195">Conclusion</offsets></title><p><offsets xml_i="5211" xml_f="5645" txt_i="1196" txt_f="1630">Multiple physical symptoms predict response to antidepressants, but not after adjustment for baseline depression severity. Physical symptoms could be a marker of severe depression rather than an independent prognostic factor and depression should be considered in patients with multiple physical symptoms. Treatment with reboxetine conferred no advantage over citalopram in those with physical symptoms, and it is less well tolerated.</offsets></p></sec></abstract><kwd-group><title>Keywords</title><kwd>Depression</kwd><kwd>Antidepressants</kwd><kwd>Citalopram</kwd><kwd>Reboxetine</kwd><kwd>Physical symptoms</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s0005"><label><offsets xml_i="5898" xml_f="5899" txt_i="1639" txt_f="1640">1</offsets></label><title><offsets xml_i="5914" xml_f="5926" txt_i="1640" txt_f="1652">Introduction</offsets></title><p><offsets xml_i="5937" xml_f="6097" txt_i="1653" txt_f="1813">Physical symptoms, which are distinct from those considered to be symptoms of depression (for example sleep and appetite disturbance) are common in depression (</offsets><xref rid="bib17 bib3" ref-type="bibr"><offsets xml_i="6136" xml_f="6172" txt_i="1813" txt_f="1849">Haug et al., 2004; Bair et al., 2003</offsets></xref><offsets xml_i="6179" xml_f="6320" txt_i="1849" txt_f="1990">). These types of symptoms (for example a change in bowel habit or pain) are often given as the presenting complaint as opposed to low mood (</offsets><xref rid="bib5 bib27 bib25" ref-type="bibr"><offsets xml_i="6365" xml_f="6435" txt_i="1990" txt_f="2060">Bridges and Goldberg, 1985; Kirmayer et al., 1993; Keeley et al., 2004</offsets></xref><offsets xml_i="6442" xml_f="6562" txt_i="2060" txt_f="2180">). Depressed patients are 3–7 times more likely to develop multiple physical symptoms than those who are not depressed (</offsets><xref rid="bib19" ref-type="bibr"><offsets xml_i="6596" xml_f="6615" txt_i="2180" txt_f="2199">Hotopf et al., 1998</offsets></xref><offsets xml_i="6622" xml_f="6936" txt_i="2199" txt_f="2513">). In many cases, no physical explanation for these symptoms is found and even when a disease state is present, the nature or degree of the symptoms may not correlate with the known pathology. A reduction in clinician׳s ability to detect depression has been shown with increasing levels of such physical symptoms (</offsets><xref rid="bib5 bib27 bib3" ref-type="bibr"><offsets xml_i="6980" xml_f="7048" txt_i="2513" txt_f="2581">Bridges and Goldberg, 1985; Kirmayer et al., 1993; Bair et al., 2003</offsets></xref><offsets xml_i="7055" xml_f="7258" txt_i="2581" txt_f="2784">). It has been estimated that 60% of previously undetected depression cases could have been identified if all primary care patients presenting with pain conditions were examined for possible depression (</offsets><xref rid="bib24" ref-type="bibr"><offsets xml_i="7292" xml_f="7303" txt_i="2784" txt_f="2795">Katon, 1984</offsets></xref><offsets xml_i="7310" xml_f="7396" txt_i="2795" txt_f="2881">). Patients in this group are therefore at risk of receiving an inaccurate diagnosis (</offsets><xref rid="bib27 bib5" ref-type="bibr"><offsets xml_i="7435" xml_f="7484" txt_i="2881" txt_f="2930">Kirmayer et al., 1993; Bridges and Goldberg, 1985</offsets></xref><offsets xml_i="7491" xml_f="7539" txt_i="2930" txt_f="2978">), are likely to use more healthcare resources (</offsets><xref rid="bib2 bib16 bib44" ref-type="bibr"><offsets xml_i="7584" xml_f="7644" txt_i="2978" txt_f="3038">Bair, 2004; Fritzsche et al., 1999; Widmer and Cadoret, 1978</offsets></xref><offsets xml_i="7651" xml_f="7698" txt_i="3038" txt_f="3085">) and are at risk of potential iatrogenic harm.</offsets></p><p><offsets xml_i="7705" xml_f="7747" txt_i="3086" txt_f="3128">A ‘somatic depression’ has been proposed (</offsets><xref rid="bib38" ref-type="bibr"><offsets xml_i="7781" xml_f="7808" txt_i="3128" txt_f="3155">Silverstein and Patel, 2011</offsets></xref><offsets xml_i="7815" xml_f="8206" txt_i="3155" txt_f="3546">) that is more prevalent in women. The authors found that those who exhibited depression accompanied by multiple physical symptoms had a poorer response to antidepressants compared with the other depressed participants. Other studies have supported the theory that patients who have a depression with multiple physical symptoms have a poorer outcome in response to antidepressant treatment (</offsets><xref rid="bib31 bib30 bib2 bib18" ref-type="bibr"><offsets xml_i="8257" xml_f="8340" txt_i="3546" txt_f="3629">Papakostas et al., 2003; Papakostas et al., 2008; Bair, 2004; Hoencamp et al., 1994</offsets></xref><offsets xml_i="8347" xml_f="8374" txt_i="3629" txt_f="3656">) problem-solving therapy (</offsets><xref rid="bib21" ref-type="bibr"><offsets xml_i="8408" xml_f="8431" txt_i="3656" txt_f="3679">Huijbregts et al., 2010</offsets></xref><offsets xml_i="8438" xml_f="8464" txt_i="3679" txt_f="3705">) and collaborative care (</offsets><xref rid="bib20" ref-type="bibr"><offsets xml_i="8498" xml_f="8521" txt_i="3705" txt_f="3728">Huijbregts et al., 2013</offsets></xref><offsets xml_i="8528" xml_f="8573" txt_i="3728" txt_f="3773">). The Papakostas study of 2008 was a large (</offsets><italic><offsets xml_i="8581" xml_f="8582" txt_i="3773" txt_f="3774">n</offsets></italic><offsets xml_i="8591" xml_f="8746" txt_i="3774" txt_f="3929">=570), flexible dose, open-label trial of fluoxetine for major depressive disorder (MDD, as defined by DSM-IV). Using a self-report Symptom Questionnaire (</offsets><xref rid="bib26" ref-type="bibr"><offsets xml_i="8780" xml_f="8793" txt_i="3929" txt_f="3942">Kellner, 1987</offsets></xref><offsets xml_i="8800" xml_f="8939" txt_i="3942" txt_f="4081">) they found that the severity of somatic anxiety symptoms of MDD at baseline predicted a worse outcome with fluoxetine. The ARTIST study (</offsets><xref rid="bib2" ref-type="bibr"><offsets xml_i="8972" xml_f="8982" txt_i="4081" txt_f="4091">Bair, 2004</offsets></xref><offsets xml_i="8989" xml_f="9068" txt_i="4091" txt_f="4170">) also demonstrated that pain is a strong predictor of poor depression outcome.</offsets></p><p><offsets xml_i="9075" xml_f="9183" txt_i="4171" txt_f="4279">The association between depression and pain becomes stronger as the severity of either condition increases (</offsets><xref rid="bib3" ref-type="bibr"><offsets xml_i="9216" xml_f="9233" txt_i="4279" txt_f="4296">Bair et al., 2003</offsets></xref><offsets xml_i="9240" xml_f="9399" txt_i="4296" txt_f="4455">). Therefore, an alternative theory is that patients with multiple physical symptoms have a more severe depression at baseline and therefore a poor prognosis. </offsets><xref rid="bib12" ref-type="bibr"><offsets xml_i="9433" xml_f="9455" txt_i="4455" txt_f="4477">Denninger et al. (2006</offsets></xref><offsets xml_i="9462" xml_f="9645" txt_i="4477" txt_f="4660">) reported that baseline somatic scores are related to baseline severity of depression. Severe depression at baseline predicts lower rates of remission with antidepressant treatment (</offsets><xref rid="bib35 bib41" ref-type="bibr"><offsets xml_i="9685" xml_f="9724" txt_i="4660" txt_f="4699">Rush et al., 2008; Trivedi et al., 2006</offsets></xref><offsets xml_i="9731" xml_f="10115" txt_i="4699" txt_f="5083">). This means that in order to understand the relationship between multiple physical symptoms in depression and prognosis with antidepressant treatment, the baseline severity of the depression must be taken in to account and adjusted for in the analysis. This has not been done in some of the studies that have predicted a poor outcome for depression with multiple physical symptoms (</offsets><xref rid="bib38 bib31" ref-type="bibr"><offsets xml_i="10155" xml_f="10207" txt_i="5083" txt_f="5135">Silverstein and Patel, 2011; Papakostas et al., 2003</offsets></xref><offsets xml_i="10214" xml_f="10216" txt_i="5135" txt_f="5137">).</offsets></p><p><offsets xml_i="10223" xml_f="10426" txt_i="5138" txt_f="5341">Moderators are factors that predict differential treatment response. Identifying a moderator of antidepressant effect in patients with multiple physical symptoms has obvious clinical and economic value (</offsets><xref rid="bib42" ref-type="bibr"><offsets xml_i="10460" xml_f="10481" txt_i="5341" txt_f="5362">Trusheim et al., 2007</offsets></xref><offsets xml_i="10488" xml_f="10739" txt_i="5362" txt_f="5613">). Matching patients to treatments using particular patient characteristics (such as genetic polymorphisms or symptom profile) is called stratified or personalised medicine. Its benefits have been demonstrated with a number of anticancer medications (</offsets><xref rid="bib42" ref-type="bibr"><offsets xml_i="10773" xml_f="10794" txt_i="5613" txt_f="5634">Trusheim et al., 2007</offsets></xref><offsets xml_i="10801" xml_f="10876" txt_i="5634" txt_f="5709">). Psychiatrists commonly select antidepressants based on symptom profile (</offsets><xref rid="bib47" ref-type="bibr"><offsets xml_i="10910" xml_f="10932" txt_i="5709" txt_f="5731">Zimmerman et al., 2004</offsets></xref><offsets xml_i="10939" xml_f="11000" txt_i="5731" txt_f="5792">), but due to an absence of established clinical moderators (</offsets><xref rid="bib39" ref-type="bibr"><offsets xml_i="11034" xml_f="11056" txt_i="5792" txt_f="5814">Simon and Perlis, 2010</offsets></xref><offsets xml_i="11063" xml_f="11114" txt_i="5814" txt_f="5865">), there is limited evidence to inform this choice.</offsets></p><p><offsets xml_i="11121" xml_f="11250" txt_i="5866" txt_f="5995">It is thought that brain mechanisms concerned with depression and pain both involve the monoamine projections from the midbrain (</offsets><xref rid="bib3" ref-type="bibr"><offsets xml_i="11283" xml_f="11300" txt_i="5995" txt_f="6012">Bair et al., 2003</offsets></xref><offsets xml_i="11307" xml_f="11396" txt_i="6012" txt_f="6101">). Noradrenaline is implicated in the aetiology of MDD and has been studied extensively (</offsets><xref rid="bib34" ref-type="bibr"><offsets xml_i="11430" xml_f="11456" txt_i="6101" txt_f="6127">Ressler and Nemeroff, 1999</offsets></xref><offsets xml_i="11463" xml_f="11576" txt_i="6127" txt_f="6240">). There is some evidence to suggest a relationship between noradrenaline and depression with physical symptoms (</offsets><xref rid="bib14" ref-type="bibr"><offsets xml_i="11610" xml_f="11620" txt_i="6240" txt_f="6250">Fava, 2003</offsets></xref><offsets xml_i="11627" xml_f="11841" txt_i="6250" txt_f="6464">). Dual acting agents (with an effect on serotonin and noradrenaline) have been reported as superior to selective serotonin re-uptake inhibitors (SSRIs) in treating the somatic symptoms associated with depression (</offsets><xref rid="bib11 bib15" ref-type="bibr"><offsets xml_i="11881" xml_f="11910" txt_i="6464" txt_f="6493">Delgado, 2004; Fishbain, 2000</offsets></xref><offsets xml_i="11917" xml_f="11920" txt_i="6493" txt_f="6496">). </offsets><xref rid="bib23" ref-type="bibr"><offsets xml_i="11954" xml_f="11971" txt_i="6496" txt_f="6513">Kang et al. (2009</offsets></xref><offsets xml_i="11978" xml_f="12347" txt_i="6513" txt_f="6882">) found that venlafaxine (a serotonin–noradrenaline re-uptake inhibitor) and mirtazipine (a noradrenergic and specific serotonergic receptor antagonist antidepressant) improved depressive symptoms in those with a diagnosis of MDD and somatic symptoms. Based on this evidence, the presence of physical symptoms could be a moderator of treatment in those with depression.</offsets></p><p><offsets xml_i="12354" xml_f="12827" txt_i="6883" txt_f="7356">Stratified medicine aims to personalise treatment based on characteristics of an individual. One way of providing evidence to stratify antidepressant treatment is to compare two treatments in a group of patients and see if any particular characteristic moderates the relationship between treatment and outcome (18). The GenPoD trial looked at two potential moderators of response to antidepressants; (1) a polymorphism in the 5HTTLPR gene (the serotonin transporter gene) (</offsets><xref rid="bib28" ref-type="bibr"><offsets xml_i="12861" xml_f="12879" txt_i="7356" txt_f="7374">Lewis et al., 2011</offsets></xref><offsets xml_i="12886" xml_f="12917" txt_i="7374" txt_f="7405">) and (2) depression severity (</offsets><xref rid="bib45" ref-type="bibr"><offsets xml_i="12951" xml_f="12969" txt_i="7405" txt_f="7423">Wiles et al., 2012</offsets></xref><offsets xml_i="12976" xml_f="13365" txt_i="7423" txt_f="7812">). There was no evidence that either moderated treatment response. In this study, we used GenPod data to investigate the following hypotheses: (1) that those with multiple baseline physical symptoms do worse with antidepressant treatment at 6 and 12 weeks; and (2) that reboxetine is better than citalopram in treating patients with depression who have multiple baseline physical symptoms.</offsets></p></sec><sec sec-type="methods" id="s0010"><label><offsets xml_i="13417" xml_f="13418" txt_i="7814" txt_f="7815">2</offsets></label><title><offsets xml_i="13433" xml_f="13440" txt_i="7815" txt_f="7822">Methods</offsets></title><sec id="s0015"><label><offsets xml_i="13471" xml_f="13474" txt_i="7823" txt_f="7826">2.1</offsets></label><title><offsets xml_i="13489" xml_f="13501" txt_i="7826" txt_f="7838">GenPoD trial</offsets></title><p><offsets xml_i="13512" xml_f="13635" txt_i="7839" txt_f="7962">This is a secondary analysis of data from the GenPoD trial, whose trial protocol and main results are published elsewhere (</offsets><xref rid="bib28 bib40" ref-type="bibr"><offsets xml_i="13675" xml_f="13714" txt_i="7962" txt_f="8001">Lewis et al., 2011; Thomas et al., 2008</offsets></xref><offsets xml_i="13721" xml_f="14127" txt_i="8001" txt_f="8407">). In brief, GenPoD is a multi-centre Randomised Controlled Trial (RCT) conducted in Bristol, Birmingham and Newcastle, UK. Participants were patients aged 18–74 years referred to the trial by their General Practitioner (GP) following agreement to prescribe an antidepressant. Eligibility criteria included a diagnosis of ICD-10 depressive episode F32 from the Clinical Interview Schedule-Revised (CIS-R) (</offsets><xref rid="bib29" ref-type="bibr"><offsets xml_i="14161" xml_f="14179" txt_i="8407" txt_f="8425">Lewis et al., 1992</offsets></xref><offsets xml_i="14186" xml_f="14233" txt_i="8425" txt_f="8472">) and a Beck Depression Inventory II (BDI-II) (</offsets><xref rid="bib4" ref-type="bibr"><offsets xml_i="14266" xml_f="14279" txt_i="8472" txt_f="8485">Beck At, 1961</offsets></xref><offsets xml_i="14286" xml_f="14709" txt_i="8485" txt_f="8908">) score of ≥15. Exclusion criteria included having taken an antidepressant in the two weeks preceding baseline assessment and those who could not complete the self-administered scales. The GPs excluded those with medical contraindications to antidepressant treatment, those with psychosis, bipolar affective disorder or major substance or alcohol abuse. Chronic physical illness was not a contraindication to participation.</offsets></p></sec><sec id="s0020"><label><offsets xml_i="14742" xml_f="14745" txt_i="8910" txt_f="8913">2.2</offsets></label><title><offsets xml_i="14760" xml_f="14773" txt_i="8913" txt_f="8926">Randomisation</offsets></title><p><offsets xml_i="14784" xml_f="15492" txt_i="8927" txt_f="9632">Participants were randomised to receive either reboxetine (4 mg twice daily) or citalopram (20 mg once daily) after giving informed consent. Randomisation was conducted using a computer-generated code, centrally administered and communicated by telephone. The randomisation was stratified by symptom severity (CIS-R &lt;28 or≥28) and centre using variable block sizes. Neither participants nor researchers were blinded to allocation. The researcher gave the medication to the participant. Initially, those prescribed reboxetine were given a dose of 2 mg twice daily, which was increased to 4 mg twice daily after four days. Participants were advised to contact their GP if they wished to increase their dose.</offsets></p></sec><sec id="s0025"><label><offsets xml_i="15525" xml_f="15528" txt_i="9634" txt_f="9637">2.3</offsets></label><title><offsets xml_i="15543" xml_f="15562" txt_i="9637" txt_f="9656">Depression measures</offsets></title><p><offsets xml_i="15573" xml_f="15847" txt_i="9657" txt_f="9931">The CIS-R was completed at baseline. This is a fully structured interview measuring common psychological symptoms present in the week prior to interview. It encompasses 14 symptom groups with the aim of identifying and characterising the symptoms of anxiety and depression (</offsets><xref rid="bib29" ref-type="bibr"><offsets xml_i="15881" xml_f="15899" txt_i="9931" txt_f="9949">Lewis et al., 1992</offsets></xref><offsets xml_i="15906" xml_f="16002" txt_i="9949" txt_f="10045">). The BDI-II measures the severity of depression and was completed at baseline, 6 and 12 weeks.</offsets></p></sec><sec id="s0030"><label><offsets xml_i="16035" xml_f="16038" txt_i="10047" txt_f="10050">2.4</offsets></label><title><offsets xml_i="16053" xml_f="16070" txt_i="10050" txt_f="10067">Exposure measures</offsets></title><p><offsets xml_i="16081" xml_f="16255" txt_i="10068" txt_f="10242">The exposure variable of interest in this study was the presence of physical symptoms at baseline. This was measured using a modified form of the Toronto Side Effects Scale (</offsets><xref rid="bib43" ref-type="bibr"><offsets xml_i="16289" xml_f="16312" txt_i="10242" txt_f="10265">Vanderkooy et al., 2002</offsets></xref><offsets xml_i="16319" xml_f="16525" txt_i="10265" txt_f="10471">). For this purpose, the scale was used to measure physical symptoms at baseline before the participants had started the study medication. The modified scale used is included in the supplementary material (</offsets><xref rid="s0100" ref-type="sec"><offsets xml_i="16558" xml_f="16578" txt_i="10471" txt_f="10491">Supplementary Fig. 1</offsets></xref><offsets xml_i="16585" xml_f="16799" txt_i="10491" txt_f="10705">). Symptoms that closely resembled symptoms of depression (agitation, daytime drowsiness and difficulty sleeping) were removed from the analysis since they are included in DSM-IV major depressive episode criteria (</offsets><xref rid="bib1" ref-type="bibr"><offsets xml_i="16832" xml_f="16870" txt_i="10705" txt_f="10743">American Psychiatric Association, 2013</offsets></xref><offsets xml_i="16877" xml_f="17023" txt_i="10743" txt_f="10889">). Gender-specific items (breast swelling, difficulty ejaculating and impotence) were also removed, leaving a total of 24 symptoms. Participants (</offsets><italic><offsets xml_i="17031" xml_f="17032" txt_i="10889" txt_f="10890">n</offsets></italic><offsets xml_i="17041" xml_f="17169" txt_i="10890" txt_f="11018">=601) were grouped into roughly equal quartiles by the number of physical symptoms they experienced; none (0 physical symptoms, </offsets><italic><offsets xml_i="17177" xml_f="17178" txt_i="11018" txt_f="11019">n</offsets></italic><offsets xml_i="17187" xml_f="17219" txt_i="11019" txt_f="11051">=161), few (1 physical symptom, </offsets><italic><offsets xml_i="17227" xml_f="17228" txt_i="11051" txt_f="11052">n</offsets></italic><offsets xml_i="17237" xml_f="17276" txt_i="11052" txt_f="11091">=126), several (2–3 physical symptoms, </offsets><italic><offsets xml_i="17284" xml_f="17285" txt_i="11091" txt_f="11092">n</offsets></italic><offsets xml_i="17294" xml_f="17338" txt_i="11092" txt_f="11136">=156) and multiple (4–16 physical symptoms, </offsets><italic><offsets xml_i="17346" xml_f="17347" txt_i="11136" txt_f="11137">n</offsets></italic><offsets xml_i="17356" xml_f="17505" txt_i="11137" txt_f="11286">=158) for 4–7 days of the week. Other measures used in the analysis included Social Support Score from the Psychiatric Morbidity among Adults Study (</offsets><xref rid="bib37" ref-type="bibr"><offsets xml_i="17539" xml_f="17567" txt_i="11286" txt_f="11314">Sherbourne and Stewart, 1991</offsets></xref><offsets xml_i="17574" xml_f="17626" txt_i="11314" txt_f="11366">), the AUDIT score for harmful alcohol consumption (</offsets><xref rid="bib36" ref-type="bibr"><offsets xml_i="17660" xml_f="17681" txt_i="11366" txt_f="11387">Saunders et al., 1993</offsets></xref><offsets xml_i="17688" xml_f="17776" txt_i="11387" txt_f="11475">) and the Short Form Health Survey- 12, a measure of physical and mental health status (</offsets><xref rid="bib22" ref-type="bibr"><offsets xml_i="17810" xml_f="17832" txt_i="11475" txt_f="11497">Jenkinson et al., 1997</offsets></xref><offsets xml_i="17839" xml_f="17841" txt_i="11497" txt_f="11499">).</offsets></p></sec><sec id="s0035"><label><offsets xml_i="17874" xml_f="17877" txt_i="11501" txt_f="11504">2.5</offsets></label><title><offsets xml_i="17892" xml_f="17908" txt_i="11504" txt_f="11520">Outcome measures</offsets></title><p><offsets xml_i="17919" xml_f="18228" txt_i="11521" txt_f="11830">For the linear regression model, the outcome was BDI-II score at 6 and 12 weeks, a continuous variable. In order to make the results comparable to previous studies, a logistic regression model was also used, In this model, a binary variable of BDI-II of less than 10 was used at 6 weeks, to indicate recovery.</offsets></p></sec><sec id="s0040"><label><offsets xml_i="18261" xml_f="18264" txt_i="11832" txt_f="11835">2.6</offsets></label><title><offsets xml_i="18279" xml_f="18305" txt_i="11835" txt_f="11861">Statistical considerations</offsets></title><p><offsets xml_i="18316" xml_f="18924" txt_i="11862" txt_f="12470">We used linear regression and logistic regression to examine the hypotheses of this study. Separate models were run at 6 and 12 weeks (linear regression model only). All models were adjusted for the trial design variables of baseline CIS-R score, medication allocation and recruitment centre. Further adjustment was made for the following potential confounders: baseline BDI-II score, adherence at 6 and 12 weeks, Social Support Score, life events score, gender, previous history of depression, age, centre, allocation, harmful alcohol use, baseline anxiety (using the Hospital Anxiety and Depression scale (</offsets><xref rid="bib46" ref-type="bibr"><offsets xml_i="18958" xml_f="18982" txt_i="12470" txt_f="12494">Zigmond and Snaith, 1983</offsets></xref><offsets xml_i="18989" xml_f="19376" txt_i="12494" txt_f="12881">) and chronic illness. The regression model included an interaction term between treatment (citalopram or reboxetine) and number of baseline physical symptoms to examine whether reboxetine is more effective than citalopram at treating depression with multiple baseline physical symptoms. As has been previously reported, age and life events were associated with missing data at 6 weeks (</offsets><xref rid="bib45 bib28" ref-type="bibr"><offsets xml_i="19416" xml_f="19454" txt_i="12881" txt_f="12919">Wiles et al., 2012; Lewis et al., 2011</offsets></xref><offsets xml_i="19461" xml_f="19649" txt_i="12919" txt_f="13107">). These factors were included in the regression model to investigate the impact of missing data on our findings. This method should address any bias under a missing at random assumption (</offsets><xref rid="bib8" ref-type="bibr"><offsets xml_i="19682" xml_f="19709" txt_i="13107" txt_f="13134">Carpenter and Kenward, 2004</offsets></xref><offsets xml_i="19716" xml_f="19773" txt_i="13134" txt_f="13191">). Analysis was performed on an intention-to-treat basis.</offsets></p><p><offsets xml_i="19780" xml_f="19929" txt_i="13192" txt_f="13341">Details of the sample size calculations for the trial and the impact of the final recruitment figures on the power of the study are given elsewhere (</offsets><xref rid="bib40" ref-type="bibr"><offsets xml_i="19963" xml_f="19982" txt_i="13341" txt_f="13360">Thomas et al., 2008</offsets></xref><offsets xml_i="19989" xml_f="20211" txt_i="13360" txt_f="13582">). The GenPoD trial was adequately powered to address the original questions of the differential response to treatment and we used confidence intervals to guide our interpretation of the clinical importance of the results.</offsets></p></sec></sec><sec sec-type="results" id="s0045"><label><offsets xml_i="20269" xml_f="20270" txt_i="13585" txt_f="13586">3</offsets></label><title><offsets xml_i="20285" xml_f="20292" txt_i="13586" txt_f="13593">Results</offsets></title><sec id="s0050"><label><offsets xml_i="20323" xml_f="20326" txt_i="13594" txt_f="13597">3.1</offsets></label><title><offsets xml_i="20341" xml_f="20374" txt_i="13597" txt_f="13630">Trial participation and follow-up</offsets></title><p><offsets xml_i="20385" xml_f="20469" txt_i="13631" txt_f="13715">In the GenPoD trial, 601 participants were randomised to receive either citalopram (</offsets><italic><offsets xml_i="20477" xml_f="20478" txt_i="13715" txt_f="13716">n</offsets></italic><offsets xml_i="20487" xml_f="20508" txt_i="13716" txt_f="13737">=298) or reboxetine (</offsets><italic><offsets xml_i="20516" xml_f="20517" txt_i="13737" txt_f="13738">n</offsets></italic><offsets xml_i="20526" xml_f="20568" txt_i="13738" txt_f="13780">=303). At six weeks, 91% of participants (</offsets><italic><offsets xml_i="20576" xml_f="20577" txt_i="13780" txt_f="13781">n</offsets></italic><offsets xml_i="20586" xml_f="20636" txt_i="13781" txt_f="13831">=546) were included in the follow-up (citalopram: </offsets><italic><offsets xml_i="20644" xml_f="20645" txt_i="13831" txt_f="13832">n</offsets></italic><offsets xml_i="20654" xml_f="20672" txt_i="13832" txt_f="13850">=274; reboxetine: </offsets><italic><offsets xml_i="20680" xml_f="20681" txt_i="13850" txt_f="13851">n</offsets></italic><offsets xml_i="20690" xml_f="20738" txt_i="13851" txt_f="13899">=272). 81% completed the twelve week follow-up (</offsets><italic><offsets xml_i="20746" xml_f="20747" txt_i="13899" txt_f="13900">n</offsets></italic><offsets xml_i="20756" xml_f="20774" txt_i="13900" txt_f="13918">=486, citalopram: </offsets><italic><offsets xml_i="20782" xml_f="20783" txt_i="13918" txt_f="13919">n</offsets></italic><offsets xml_i="20792" xml_f="20810" txt_i="13919" txt_f="13937">=252; reboxetine: </offsets><italic><offsets xml_i="20818" xml_f="20819" txt_i="13937" txt_f="13938">n</offsets></italic><offsets xml_i="20828" xml_f="21133" txt_i="13938" txt_f="14243">=233). Some participants received an increase dosage of their antidepressant from their GP. For citalopram, 11 had their dosage increased to 30 mg/day, 33–40 mg/day and 11–60 mg (with one having an increase to an unknown amount). For reboxetine, 3 increased to 10 mg/day, 9–12 mg/day and one to 16 mg/day.</offsets></p></sec><sec id="s0055"><label><offsets xml_i="21166" xml_f="21169" txt_i="14245" txt_f="14248">3.2</offsets></label><title><offsets xml_i="21184" xml_f="21241" txt_i="14248" txt_f="14305">Distribution of physical symptoms in the trial population</offsets></title><p><xref rid="f0005" ref-type="fig"><offsets xml_i="21285" xml_f="21291" txt_i="14306" txt_f="14312">Fig. 1</offsets></xref><offsets xml_i="21298" xml_f="21488" txt_i="14312" txt_f="14502"> shows the distribution of physical symptoms present for 4–7 days in the previous week. The mean number of physical symptoms experienced for 4–7 days/week was 2.55 (standard deviation 2.77).</offsets></p></sec><sec id="s0060"><label><offsets xml_i="21521" xml_f="21524" txt_i="14504" txt_f="14507">3.3</offsets></label><title><offsets xml_i="21539" xml_f="21580" txt_i="14507" txt_f="14548">Baseline comparability of severity groups</offsets></title><p><xref rid="t0005" ref-type="table"><offsets xml_i="21626" xml_f="21633" txt_i="14549" txt_f="14556">Table 1</offsets></xref><offsets xml_i="21640" xml_f="21946" txt_i="14556" txt_f="14862"> shows the baseline characteristics of the symptom quartiles. Individuals in the multiple physical symptoms group were more likely to be female (73% vs. 61%), report chronic illness (57% vs. 40%) and had a higher score on the BDI-II (37.94 vs. 29.67) than individuals with no physical symptoms at baseline.</offsets></p></sec><sec id="s0065"><label><offsets xml_i="21979" xml_f="21982" txt_i="14864" txt_f="14867">3.4</offsets></label><title><offsets xml_i="21997" xml_f="22081" txt_i="14867" txt_f="14951">Multiple physical symptoms and change in BDI-II score in response to antidepressants</offsets></title><p><xref rid="t0010" ref-type="table"><offsets xml_i="22127" xml_f="22134" txt_i="14952" txt_f="14959">Table 2</offsets></xref><offsets xml_i="22141" xml_f="22742" txt_i="14959" txt_f="15560"> shows adjusted differences in mean BDI-II score between no physical symptoms and few, several and multiple physical symptoms at 6 and 12 weeks for all treatments using the linear regression model. Before adjusting for baseline BDI-II, there was a large difference in mean BDI-II between no and multiple physical symptoms, at 6 (4.50 95% CI 1.87, 7.14) and 12 weeks (4.51 95% CI 1.60, 7.42). After adjusting for baseline BDI-II, the CIs included the null at 6 weeks (2.17 95% CI −0.39, 4.73) and 12 weeks (2.43 95% CI −0.46, 5.32). No other confounders had a substantial influence on the association. </offsets><xref rid="f0010" ref-type="fig"><offsets xml_i="22775" xml_f="22781" txt_i="15560" txt_f="15566">Fig. 2</offsets></xref><offsets xml_i="22788" xml_f="22874" txt_i="15566" txt_f="15652"> shows BDI-II scores at baseline, 6 and 12 weeks stratified by physical symptom group.</offsets></p><p><offsets xml_i="22881" xml_f="23160" txt_i="15653" txt_f="15932">The logistic regression model also produced no evidence to suggest that individuals reporting 3 or more physical symptoms at baseline were less likely to have a BDI score of less than 10 at 6 weeks than individuals with no physical symptoms at baseline (1.06, 95% CI 0.56, 2.00).</offsets></p></sec><sec id="s0070"><label><offsets xml_i="23193" xml_f="23196" txt_i="15934" txt_f="15937">3.5</offsets></label><title><offsets xml_i="23211" xml_f="23291" txt_i="15937" txt_f="16017">Citalopram vs. reboxetine in treating depression with multiple physical symptoms</offsets></title><p><offsets xml_i="23302" xml_f="23609" txt_i="16018" txt_f="16325">We tested for an interaction between the physical symptom group and the randomised treatment, with BDI-II score (a continuous variable) at 6 and 12 weeks as the outcome. This provided no evidence that reboxetine was more effective than citalopram in those with multiple physical symptoms, at 6 (interaction </offsets><italic><offsets xml_i="23617" xml_f="23619" txt_i="16325" txt_f="16327">P=</offsets></italic><offsets xml_i="23628" xml_f="23660" txt_i="16327" txt_f="16359">0.18) and 12 weeks (interaction </offsets><italic><offsets xml_i="23668" xml_f="23669" txt_i="16359" txt_f="16360">P</offsets></italic><offsets xml_i="23678" xml_f="23686" txt_i="16360" txt_f="16368">=0.24). </offsets><xref rid="t0015" ref-type="table"><offsets xml_i="23721" xml_f="23728" txt_i="16368" txt_f="16375">Table 3</offsets></xref><offsets xml_i="23735" xml_f="24017" txt_i="16375" txt_f="16657"> shows mean BDI-II scores of the citalopram and reboxetine groups at 6 and 12 weeks by physical symptoms group, adjusted for trial design variables. When the analysis included factors associated with missing data (data not shown), the results were consistent with the main analysis.</offsets></p></sec></sec><sec sec-type="discussion" id="s0075"><label><offsets xml_i="24078" xml_f="24079" txt_i="16660" txt_f="16661">4</offsets></label><title><offsets xml_i="24094" xml_f="24104" txt_i="16661" txt_f="16671">Discussion</offsets></title><p><offsets xml_i="24115" xml_f="24306" txt_i="16672" txt_f="16863">Multiple physical symptoms are associated with poorer response to antidepressants but we found no evidence for this relationship after adjusting for depression severity. This is supported by </offsets><xref rid="bib12" ref-type="bibr"><offsets xml_i="24340" xml_f="24362" txt_i="16863" txt_f="16885">Denninger et al. (2006</offsets></xref><offsets xml_i="24369" xml_f="24538" txt_i="16885" txt_f="17054">) who demonstrated that physical symptom scores at baseline did not predict reduction in HAM-D score with treatment, but opposes the findings of a number other studies (</offsets><xref rid="bib38 bib32 bib2 bib25 bib31 bib18" ref-type="bibr"><offsets xml_i="24601" xml_f="24734" txt_i="17054" txt_f="17187">Silverstein and Patel, 2011, Papakostas et al., 2004; Bair, 2004; Keeley et al., 2004; Papakostas et al., 2003; Hoencamp et al., 1994</offsets></xref><offsets xml_i="24741" xml_f="24743" txt_i="17187" txt_f="17189">).</offsets></p><p><offsets xml_i="24750" xml_f="25221" txt_i="17190" txt_f="17661">There are some possible explanations for our findings. Multiple physical symptoms may represent severe depression and could be a sign of more severe illness. It could be that the severity of depression associated with multiple physical symptoms confers poor prognosis rather than the physical symptoms themselves. This is consistent with earlier theories on predictors of antidepressant response, whereby biological symptoms were used as a marker of depression severity (</offsets><xref rid="bib11" ref-type="bibr"><offsets xml_i="25255" xml_f="25268" txt_i="17661" txt_f="17674">Delgado, 2004</offsets></xref><offsets xml_i="25275" xml_f="25572" txt_i="17674" txt_f="17971">). It is possible multiple physical symptoms represent a misinterpretation of physical sensations, that is more likely to occur in depression and would usually be ignored by someone without depression. Therefore the more severe the depression, the more extreme the experience of physical symptoms.</offsets></p><p><offsets xml_i="25579" xml_f="25811" txt_i="17972" txt_f="18204">An alternative theory is that increased physical symptoms are associated with an underlying physical condition that leads to poor health and consequently depression. Inflammatory processes have been implicated in this relationship (</offsets><xref rid="bib33" ref-type="bibr"><offsets xml_i="25845" xml_f="25864" txt_i="18204" txt_f="18223">Raison et al., 2006</offsets></xref><offsets xml_i="25871" xml_f="26161" txt_i="18223" txt_f="18513">). In our study, adjusting for chronic illness made little difference to the difference in mean BDI-II score between no and high scores at 6 weeks (4.16 95% CI 1.52, 6.81 vs. 4.50 95% CI 1.87, 7.14) and only a small difference at 12 weeks (3.74 95% CI 0.84, 6.65vs. 4.51 95% CI 1.60, 7.42).</offsets></p><p><offsets xml_i="26168" xml_f="26212" txt_i="18514" txt_f="18558">Contrary to our findings, other large RCTs (</offsets><xref rid="bib2 bib38 bib31 bib30 bib18 bib25" ref-type="bibr"><offsets xml_i="26275" xml_f="26408" txt_i="18558" txt_f="18691">Bair, 2004; Silverstein and Patel, 2011; Papakostas et al., 2003; Papakostas et al., 2008; Hoencamp et al., 1994; Keeley et al., 2004</offsets></xref><offsets xml_i="26415" xml_f="26782" txt_i="18691" txt_f="19058">), have demonstrated that the presence of physical symptoms at baseline predicts an increased likelihood of non-response to an antidepressant. There are several possible explanations for this involving the method of data collection and/or data analysis. The most important difference is that some of these studies did not control for baseline severity of depression (</offsets><xref rid="bib38 bib31" ref-type="bibr"><offsets xml_i="26822" xml_f="26874" txt_i="19058" txt_f="19110">Silverstein and Patel, 2011; Papakostas et al., 2003</offsets></xref><offsets xml_i="26881" xml_f="27024" txt_i="19110" txt_f="19253">). Therefore, those individuals with a poor prognosis who had more somatic symptoms could have been more severely depressed in the first place.</offsets></p><p><offsets xml_i="27031" xml_f="27093" txt_i="19254" txt_f="19316">We used a modified version of the Toronto Side Effects Scale (</offsets><xref rid="bib43" ref-type="bibr"><offsets xml_i="27127" xml_f="27150" txt_i="19316" txt_f="19339">Vanderkooy et al., 2002</offsets></xref><offsets xml_i="27157" xml_f="27329" txt_i="19339" txt_f="19511">) to measure physical symptoms. This is a broad screening tool encompassing different types of physical symptoms in multiple modalities. The Kellner symptom questionnaire (</offsets><xref rid="bib26" ref-type="bibr"><offsets xml_i="27363" xml_f="27376" txt_i="19511" txt_f="19524">Kellner, 1987</offsets></xref><offsets xml_i="27383" xml_f="27405" txt_i="19524" txt_f="19546">) used by Papakostas (</offsets><xref rid="bib30 bib31" ref-type="bibr"><offsets xml_i="27445" xml_f="27474" txt_i="19546" txt_f="19575">Papakostas et al., 2008, 2003</offsets></xref><offsets xml_i="27481" xml_f="27499" txt_i="19575" txt_f="19593">) and the SCL-90 (</offsets><xref rid="bib13" ref-type="bibr"><offsets xml_i="27533" xml_f="27555" txt_i="19593" txt_f="19615">Derogatis et al., 1973</offsets></xref><offsets xml_i="27562" xml_f="27571" txt_i="19615" txt_f="19624">) used by</offsets><xref rid="bib18" ref-type="bibr"><offsets xml_i="27605" xml_f="27626" txt_i="19624" txt_f="19645">Hoencamp et al. (1994</offsets></xref><offsets xml_i="27633" xml_f="27639" txt_i="19645" txt_f="19651">) and </offsets><xref rid="bib30" ref-type="bibr"><offsets xml_i="27673" xml_f="27696" txt_i="19651" txt_f="19674">Papakostas et al. (2008</offsets></xref><offsets xml_i="27703" xml_f="27822" txt_i="19674" txt_f="19793">), include symptoms of depression such as poor appetite, and anxiety symptoms such as a choking feeling or hot spells. </offsets><xref rid="bib25" ref-type="bibr"><offsets xml_i="27856" xml_f="27876" txt_i="19793" txt_f="19813">Keeley et al. (2004)</offsets></xref><offsets xml_i="27883" xml_f="28440" txt_i="19813" txt_f="20370"> have considered DSM-IV physical complaints associated with depression, generalised anxiety disorder and panic disorder as their measure of baseline physical symptoms. We excluded any symptoms that resembled well- established somatic symptoms of depression (for example, insomnia) and adjusted for anxiety in our analysis using a scale that avoided asking about the physical symptoms of anxiety (to prevent overcorrection) in case this was a confounder. Our data demonstrated that baseline anxiety was not a confounder but other studies have not done this (</offsets><xref rid="bib38 bib30" ref-type="bibr"><offsets xml_i="28480" xml_f="28532" txt_i="20370" txt_f="20422">Silverstein and Patel, 2011; Papakostas et al., 2008</offsets></xref><offsets xml_i="28539" xml_f="28706" txt_i="20422" txt_f="20589">). One possible explanation for these contradictory finding could be that the physical symptoms scale used in prior studies had an overlap with symptoms of depression.</offsets></p><p><offsets xml_i="28713" xml_f="28740" txt_i="20590" txt_f="20617">Papakostas and colleagues (</offsets><xref rid="bib30" ref-type="bibr"><offsets xml_i="28774" xml_f="28797" txt_i="20617" txt_f="20640">Papakostas et al., 2008</offsets></xref><offsets xml_i="28804" xml_f="29317" txt_i="20640" txt_f="21153">) demonstrated an association between multiple physical symptoms and treatment response even after adjusting for baseline depression severity, and our study does not. It is difficult to fully explain this difference. As they have not presented their data before adjusting for baseline depression, we do not know what contribution this has made to the results. This makes their results hard to interpret. The association they found between baseline somatic scores and treatment response (OR 0.96 95% CI 0.94–0.98, </offsets><italic><offsets xml_i="29325" xml_f="29327" txt_i="21153" txt_f="21155">P=</offsets></italic><offsets xml_i="29336" xml_f="29809" txt_i="21155" txt_f="21628">0.002) was statistically significant. Since a 3-point difference in the BDI-II score corresponds to a minimally important clinical difference (NICE guidelines, 2004), this difference may not have clinical relevance. Similarly, our 95% CIs indicate that individuals reporting multiple physical symptoms at baseline may score up to 4 points higher on the BDI at 6 (2.17, 95% CI −0.39, 4.75 and 12 weeks (2.43, 95% CI −0.46, 5.32), which may also not be of clinical relevance.</offsets></p><p><offsets xml_i="29816" xml_f="30090" txt_i="21629" txt_f="21903">There was no evidence of a difference between citalopram and reboxetine in treating depression with multiple baseline physical symptoms and no evidence that physical symptoms are a moderator of the antidepressant effect of SSRIs and NARIs. Using data from the GenPod trial, </offsets><xref rid="bib45" ref-type="bibr"><offsets xml_i="30124" xml_f="30143" txt_i="21903" txt_f="21922">Wiles et al. (2012)</offsets></xref><offsets xml_i="30150" xml_f="30601" txt_i="21922" txt_f="22373"> also found that treatment with NARIs did not confer any advantage over SSRI treatment for outcome in those with more severe depression. Therefore, noradrenergic antidepressants do not appear to be superior to serotonergic antidepressants in treating depression in those with multiple physical symptoms or those with more severe depression in this primary care population. Since reboxetine was associated with more adverse effects and more drop-outs (</offsets><xref rid="bib9 bib10" ref-type="bibr"><offsets xml_i="30640" xml_f="30684" txt_i="22373" txt_f="22417">Cipriani et al., 2009; Crawford et al., 2014</offsets></xref><offsets xml_i="30691" xml_f="30761" txt_i="22417" txt_f="22487">), this suggests that other agents should take preference over a NARI.</offsets></p><p><offsets xml_i="30768" xml_f="31181" txt_i="22488" txt_f="22901">The GenPoD trial is a suitable data set to address both our hypotheses. Data were collected from primary care patient with a diagnosis of severe depression (mean baseline BDI was 33.7). It compared two different classes of antidepressants to see whether a specific patient characteristic moderates the relationship between treatment type and outcome. This is an appropriate way of testing for a moderator effect (</offsets><xref rid="bib39" ref-type="bibr"><offsets xml_i="31215" xml_f="31237" txt_i="22901" txt_f="22923">Simon and Perlis, 2010</offsets></xref><offsets xml_i="31244" xml_f="31316" txt_i="22923" txt_f="22995">). Secondary analysis testing for moderation can suffer from low power (</offsets><xref rid="bib6 bib7" ref-type="bibr"><offsets xml_i="31354" xml_f="31387" txt_i="22995" txt_f="23028">Brookes et al., 2004; Brown, 1988</offsets></xref><offsets xml_i="31394" xml_f="31596" txt_i="23028" txt_f="23230">), but since the GenPod study was originally designed to test for an interaction effect, this was not a major issue in this case, and indeed in the event the confidence intervals were relatively narrow.</offsets></p></sec><sec id="s0080"><label><offsets xml_i="31629" xml_f="31630" txt_i="23232" txt_f="23233">5</offsets></label><title><offsets xml_i="31645" xml_f="31656" txt_i="23233" txt_f="23244">Limitations</offsets></title><p><offsets xml_i="31667" xml_f="31968" txt_i="23245" txt_f="23546">There are a few limitations to this study. Follow-up data were available for 81% of trial participants at 12 weeks. Even a small amount of missing data has the potential to introduce bias; however, adjustment for factors associated with missing data produced results consistent with our main analysis.</offsets></p><p><offsets xml_i="31975" xml_f="32116" txt_i="23547" txt_f="23688">More participants allocated to reboxetine discontinued antidepressant treatment than those allocated to citalopram (36% vs. 17% at 6 weeks) (</offsets><xref rid="bib10" ref-type="bibr"><offsets xml_i="32150" xml_f="32171" txt_i="23688" txt_f="23709">Crawford et al., 2014</offsets></xref><xref rid="bib9" ref-type="bibr"><offsets xml_i="32211" xml_f="32233" txt_i="23709" txt_f="23731">Cipriani et al. (2009)</offsets></xref><offsets xml_i="32240" xml_f="33159" txt_i="23731" txt_f="24650">. Non-adherence to treatment, particularly differential non-adherence between treatment arms, has the potential to bias estimates of treatment efficacy. The reboxetine group suffered more adverse effects, but there was not strong evidence of an association between adverse effects and drop-out. 42% of participants had discontinued their medications at 12 weeks. A lack of blinding may have introduced a source of bias as the participants knew which drug they were receiving. However, the participants would have required strong preconceptions on the effectiveness of each drug and so this is unlikely to have influenced the results. Despite the relatively large sample size it is possible that we did not have sufficient power to detect interactions, which may have resulted in type II errors; however, we have used the confidence intervals obtained to guide interpretation in respect of potential clinical importance.</offsets></p><p><offsets xml_i="33166" xml_f="33602" txt_i="24651" txt_f="25087">Finally, trial participants themselves are often a highly selected group, which can lead to issues of generalisability. On the other hand, participants were recruited from primary care, and the study included those with chronic physical illness, which is likely to increase the generalisability of the findings. Moreover, the analysis adjusted for chronic illness, baseline depression and anxiety as well as other potential confounders.</offsets></p></sec><sec sec-type="conclusions" id="s0085"><label><offsets xml_i="33658" xml_f="33659" txt_i="25089" txt_f="25090">6</offsets></label><title><offsets xml_i="33674" xml_f="33685" txt_i="25090" txt_f="25101">Conclusions</offsets></title><p><offsets xml_i="33696" xml_f="34697" txt_i="25102" txt_f="26103">Multiple baseline physical symptoms appear to predict poor response to antidepressants, but not after adjustment for depression severity. Multiple physical symptoms may represent severe depression rather than a poor prognostic factor. Clinicians should ask about mood symptoms and explore psychosocial issues in patients with multiple physical symptoms. If considering a diagnosis of depression in someone with multiple physical symptoms, clinicians should treat it as a moderate to severe depression. This is essential in order to avoid inappropriate investigation and treatment of physical symptoms, which could lead to iatrogenic harm. Reboxetine does not confer any advantage over citalopram in this group, and it is less well tolerated. Since there is no evidence that physical symptoms are a moderator of treatment in patients with multiple physical symptoms when a clinician chooses an antidepressant they should take account of the side effect profile, rather than depend on physical symptoms.</offsets></p></sec><sec id="s0090"><title><offsets xml_i="34730" xml_f="34752" txt_i="26105" txt_f="26127">Role of funding source</offsets></title><p><offsets xml_i="34763" xml_f="34794" txt_i="26128" txt_f="26159">This work was supported by the </offsets><funding-source id="GS1"><offsets xml_i="34819" xml_f="34896" txt_i="26159" txt_f="26236">Medical Research Council United Kingdom of Great Britain and Northern Ireland</offsets></funding-source><offsets xml_i="34913" xml_f="34936" txt_i="26236" txt_f="26259"> (Grant ref: G0200243).</offsets></p></sec><sec id="s0095"><title><offsets xml_i="34969" xml_f="34989" txt_i="26261" txt_f="26281">Conflict of interest</offsets></title><p><offsets xml_i="35000" xml_f="35021" txt_i="26282" txt_f="26303">No conflict declared.</offsets></p></sec></body><back><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="book" id="sbref1"><person-group person-group-type="author"><name><surname>American Psychiatric Association</surname></name></person-group><chapter-title>Diagnostic and Statistical Manual of Mental Disorders</chapter-title><edition>fifth edition</edition><year>2013</year><publisher-name>Arlington</publisher-name><publisher-loc>VA</publisher-loc><comment>(Web. (access date: 01.06.13). dsm.psychiatryonline.org.)</comment></element-citation></ref><ref id="bib2"><element-citation publication-type="journal" id="sbref2"><person-group person-group-type="author"><name><surname>Bair</surname><given-names>M.J.</given-names></name></person-group><article-title>Impact of pain on depression treatment response in primary care</article-title><source>Psychosom. Med.</source><volume>66</volume><year>2004</year><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">14747633</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sbref3"><person-group person-group-type="author"><name><surname>Bair</surname><given-names>M.J.</given-names></name><name><surname>Robinson</surname><given-names>R.L.</given-names></name><name><surname>Katon</surname><given-names>W.</given-names></name><name><surname>Kroenke</surname><given-names>K.</given-names></name></person-group><article-title>Depression and pain comorbidity: a literature review</article-title><source>Arch. Intern. Med.</source><volume>163</volume><year>2003</year><fpage>2433</fpage><lpage>2445</lpage><pub-id pub-id-type="pmid">14609780</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sbref4"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>A.T.</given-names></name><name><surname>Ward</surname><given-names>C.</given-names></name><name><surname>Mendelson</surname><given-names>M.</given-names></name><name><surname>Mock</surname><given-names>J.</given-names></name><name><surname>Erbaugh</surname><given-names>J.</given-names></name></person-group><article-title>An inventory for measuring depression</article-title><source>Arch. Gen. Psychiatry</source><volume>4</volume><year>1961</year><fpage>561</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">13688369</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sbref5"><person-group person-group-type="author"><name><surname>Bridges</surname><given-names>K.W.</given-names></name><name><surname>Goldberg</surname><given-names>D.P.</given-names></name></person-group><article-title>Somatic presentation of dsm-iii psychiatric-disorders in primary care</article-title><source>J. Psychosom. Res.</source><volume>29</volume><year>1985</year><fpage>563</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">4087223</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sbref6"><person-group person-group-type="author"><name><surname>Brookes</surname><given-names>S.T.</given-names></name><name><surname>Whitely</surname><given-names>E.</given-names></name><name><surname>Egger</surname><given-names>M.</given-names></name><name><surname>Smith</surname><given-names>G.D.</given-names></name><name><surname>Mulheran</surname><given-names>P.A.</given-names></name><name><surname>Peters</surname><given-names>T.J.</given-names></name></person-group><article-title>Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test</article-title><source>J. Clin. Epidemiol.</source><volume>57</volume><year>2004</year><fpage>229</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">15066682</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sbref7"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>W.A.</given-names></name></person-group><article-title>Predictors of placebo-response in depression</article-title><source>Psychopharmacol. Bull.</source><volume>24</volume><year>1988</year><fpage>14</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">3290937</pub-id></element-citation></ref><ref id="bib8"><mixed-citation publication-type="other" id="othref0005">Carpenter, J., Kenward, M., 2004. Guidelines for handling missing data in social science research. <ext-link ext-link-type="uri" xlink:href="http://www.missingdata.org.uk" id="ir125263">www.missingdata.org.uk</ext-link>.</mixed-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sbref8"><person-group person-group-type="author"><name><surname>Cipriani</surname><given-names>A.</given-names></name><name><surname>Furukawa</surname><given-names>T.A.</given-names></name><name><surname>Salanti</surname><given-names>G.</given-names></name><name><surname>Geddes</surname><given-names>J.R.</given-names></name><name><surname>Higgins</surname><given-names>J.P.</given-names></name><name><surname>Churchill</surname><given-names>R.</given-names></name><name><surname>Watanabe</surname><given-names>N.</given-names></name><name><surname>Nakagawa</surname><given-names>A.</given-names></name><name><surname>Omori</surname><given-names>I.M.</given-names></name><name><surname>Mcguire</surname><given-names>H.</given-names></name><name><surname>Tansella</surname><given-names>M.</given-names></name><name><surname>Barbui</surname><given-names>C.</given-names></name></person-group><article-title>Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis</article-title><source>Lancet</source><volume>373</volume><year>2009</year><fpage>746</fpage><lpage>758</lpage><pub-id pub-id-type="pmid">19185342</pub-id></element-citation></ref><ref id="bib10"><mixed-citation publication-type="other" id="othref0010">Crawford, A.A., Lewis, S., Nutt, D., Peters, T.J., Cowen, P., O’donovan, M.C., Wiles, N., Lewis, G., 2014. Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. Psychopharmacology (<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00213-014-3467-8" id="ir1258">10.1007/s00213-014-3467-8</ext-link>, e-pub ahead of print).</mixed-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sbref9"><person-group person-group-type="author"><name><surname>Delgado</surname><given-names>P.L.</given-names></name></person-group><article-title>Common pathways of depression and pain</article-title><source>J. Clin. Psychiatry</source><volume>65</volume><year>2004</year><fpage>16</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">15315473</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sbref10"><person-group person-group-type="author"><name><surname>Denninger</surname><given-names>J.W.</given-names></name><name><surname>Papakostas</surname><given-names>G.I.</given-names></name><name><surname>Mahal</surname><given-names>Y.</given-names></name><name><surname>Merens</surname><given-names>W.</given-names></name><name><surname>Alpert</surname><given-names>J.E.</given-names></name><name><surname>Nierenberg</surname><given-names>A.A.</given-names></name><name><surname>Yeung</surname><given-names>A.</given-names></name><name><surname>Fava</surname><given-names>M.</given-names></name></person-group><article-title>Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine</article-title><source>Psychosomatics</source><volume>47</volume><year>2006</year><fpage>348</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">16844895</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal" id="sbref11"><person-group person-group-type="author"><name><surname>Derogatis</surname><given-names>L.R.</given-names></name><name><surname>Lipman</surname><given-names>R.S.</given-names></name><name><surname>Covi</surname><given-names>L.</given-names></name></person-group><article-title>SCL-90: an outpatient psychiatric rating scale–preliminary report</article-title><source>Psychopharmacol. Bull.</source><volume>9</volume><year>1973</year><fpage>13</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">4682398</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="sbref12"><person-group person-group-type="author"><name><surname>Fava</surname><given-names>M.</given-names></name></person-group><article-title>The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression</article-title><source>J. Clin. Psychiatry</source><volume>64</volume><year>2003</year><fpage>26</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">14552653</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal" id="sbref13"><person-group person-group-type="author"><name><surname>Fishbain</surname><given-names>D.</given-names></name></person-group><article-title>Evidence-based data on pain relief with antidepressants</article-title><source>Ann. Med.</source><volume>32</volume><year>2000</year><fpage>305</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">10949061</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sbref14"><person-group person-group-type="author"><name><surname>Fritzsche</surname><given-names>K.</given-names></name><name><surname>Sandholzer</surname><given-names>H.</given-names></name><name><surname>Brucks</surname><given-names>U.</given-names></name><name><surname>Cierpka</surname><given-names>M.</given-names></name><name><surname>Deter</surname><given-names>H.C.</given-names></name><name><surname>Harter</surname><given-names>M.</given-names></name><name><surname>Hoger</surname><given-names>C.</given-names></name><name><surname>Richter</surname><given-names>R.</given-names></name><name><surname>Schmidt</surname><given-names>B.</given-names></name><name><surname>Larisch</surname><given-names>A.</given-names></name><name><surname>Wirsching</surname><given-names>M.</given-names></name></person-group><article-title>Psychosocial care by general practitioners–where are the problems? Results of a demonstration project on quality management in psychosocial primary care</article-title><source>Int. J. Psychiatry Med.</source><volume>29</volume><year>1999</year><fpage>395</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">10782423</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sbref15"><person-group person-group-type="author"><name><surname>Haug</surname><given-names>T.T.</given-names></name><name><surname>Mykletun</surname><given-names>A.</given-names></name><name><surname>Dahl</surname><given-names>A.A.</given-names></name></person-group><article-title>The association between anxiety, depression, and somatic symptoms in a large population: the HUNT-II study</article-title><source>Psychosom. Med.</source><volume>66</volume><year>2004</year><fpage>845</fpage><lpage>851</lpage><pub-id pub-id-type="pmid">15564348</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal" id="sbref16"><person-group person-group-type="author"><name><surname>Hoencamp</surname><given-names>E.</given-names></name><name><surname>Haffmans</surname><given-names>P.M.</given-names></name><name><surname>Duivenvoorden</surname><given-names>H.</given-names></name><name><surname>Knegtering</surname><given-names>H.</given-names></name><name><surname>Dijken</surname><given-names>W.A.</given-names></name></person-group><article-title>Predictors of (non-) response in depressed outpatients treated with a three-phase sequential medication strategy</article-title><source>J. Affect Disord.</source><volume>31</volume><year>1994</year><fpage>235</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">7989638</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal" id="sbref17"><person-group person-group-type="author"><name><surname>Hotopf</surname><given-names>M.</given-names></name><name><surname>Mayou</surname><given-names>R.</given-names></name><name><surname>Wadsworth</surname><given-names>M.</given-names></name><name><surname>Wessely</surname><given-names>S.</given-names></name></person-group><article-title>Temporal relationships between physical symptoms and psychiatric disorder. Results from a national birth cohort</article-title><source>Br. J. Psychiatry</source><volume>173</volume><year>1998</year><fpage>255</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">9926103</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal" id="sbref18"><person-group person-group-type="author"><name><surname>Huijbregts</surname><given-names>K.M.</given-names></name><name><surname>De Jong</surname><given-names>F.J.</given-names></name><name><surname>Van Marwijk</surname><given-names>H.W.</given-names></name><name><surname>Beekman</surname><given-names>A.T.</given-names></name><name><surname>Ader</surname><given-names>H.J.</given-names></name><name><surname>Van Der Feltz-Cornelis</surname><given-names>C.M.</given-names></name></person-group><article-title>A high physical symptom count reduces the effectiveness of treatment for depression, independently of chronic medical conditions</article-title><source>J. Psychosom. Res.</source><volume>74</volume><year>2013</year><fpage>179</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">23438706</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal" id="sbref19"><person-group person-group-type="author"><name><surname>Huijbregts</surname><given-names>K.M.</given-names></name><name><surname>Van Marwijk</surname><given-names>H.W.</given-names></name><name><surname>DE Jong</surname><given-names>F.J.</given-names></name><name><surname>Schreuders</surname><given-names>B.</given-names></name><name><surname>Beekman</surname><given-names>A.T.</given-names></name><name><surname>Van Der Feltz-Cornelis</surname><given-names>C.M.</given-names></name></person-group><article-title>Adverse effects of multiple physical symptoms on the course of depressive and anxiety symptoms in primary care</article-title><source>Psychother. Psychosom.</source><volume>79</volume><year>2010</year><fpage>389</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">20829652</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal" id="sbref20"><person-group person-group-type="author"><name><surname>Jenkinson</surname><given-names>C.</given-names></name><name><surname>Layte</surname><given-names>R.</given-names></name><name><surname>Lawrence</surname><given-names>K.</given-names></name></person-group><article-title>Development and testing of the medical outcomes study 36-item short form health survey summary scale scores in the United Kingdom. Results from a large-scale survey and a clinical trial</article-title><source>Med. Care</source><volume>35</volume><year>1997</year><fpage>410</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">9107208</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal" id="sbref21"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>E.H.</given-names></name><name><surname>Lee</surname><given-names>I.S.</given-names></name><name><surname>Chung</surname><given-names>S.K.</given-names></name><name><surname>Lee</surname><given-names>S.Y.</given-names></name><name><surname>Kim</surname><given-names>E.J.</given-names></name><name><surname>Hong</surname><given-names>J.P.</given-names></name><name><surname>OH</surname><given-names>K.S.</given-names></name><name><surname>WOO</surname><given-names>J.M.</given-names></name><name><surname>KIM</surname><given-names>S.</given-names></name><name><surname>Park</surname><given-names>J.E.</given-names></name><name><surname>Yu</surname><given-names>B.H.</given-names></name></person-group><article-title>Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: a randomized, open-labeled trial</article-title><source>Psychiatry Res.</source><volume>169</volume><year>2009</year><fpage>118</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">19695711</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal" id="sbref22"><person-group person-group-type="author"><name><surname>Katon</surname><given-names>W.</given-names></name></person-group><article-title>Depression: relationship to somatization and chronic medical illness</article-title><source>J. Clin. Psychiatry</source><volume>45</volume><year>1984</year><fpage>4</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">6698951</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal" id="sbref23"><person-group person-group-type="author"><name><surname>Keeley</surname><given-names>R.D.</given-names></name><name><surname>Smith</surname><given-names>J.L.</given-names></name><name><surname>Nutting</surname><given-names>P.A.</given-names></name><name><surname>Miriam Dickinson</surname><given-names>L.</given-names></name><name><surname>Perry Dickinson</surname><given-names>W.</given-names></name><name><surname>Rost</surname><given-names>K.M.</given-names></name></person-group><article-title>Does a depression intervention result in improved outcomes for patients presenting with physical symptoms?</article-title><source>J. Gen. Intern. Med.</source><volume>19</volume><year>2004</year><fpage>615</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">15209599</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal" id="sbref24"><person-group person-group-type="author"><name><surname>Kellner</surname><given-names>R.</given-names></name></person-group><article-title>A symptom questionnaire</article-title><source>J. Clin. Psychiatry</source><volume>48</volume><year>1987</year><fpage>268</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">3597327</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal" id="sbref25"><person-group person-group-type="author"><name><surname>Kirmayer</surname><given-names>L.J.</given-names></name><name><surname>Robbins</surname><given-names>J.M.</given-names></name><name><surname>Dworkind</surname><given-names>M.</given-names></name><name><surname>Yaffe</surname><given-names>M.J.</given-names></name></person-group><article-title>Somatization and the recognition of depression and anxiety in primary care</article-title><source>Am. J. Psychiatry</source><volume>150</volume><year>1993</year><fpage>734</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">8480818</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal" id="sbref26"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>G.</given-names></name><name><surname>Mulligan</surname><given-names>J.</given-names></name><name><surname>Wiles</surname><given-names>N.</given-names></name><name><surname>Cowen</surname><given-names>P.</given-names></name><name><surname>Craddock</surname><given-names>N.</given-names></name><name><surname>Ikeda</surname><given-names>M.</given-names></name><name><surname>Grozeva</surname><given-names>D.</given-names></name><name><surname>Mason</surname><given-names>V.</given-names></name><name><surname>Nutt</surname><given-names>D.</given-names></name><name><surname>Sharp</surname><given-names>D.</given-names></name><name><surname>Tallon</surname><given-names>D.</given-names></name><name><surname>Thomas</surname><given-names>L.</given-names></name><name><surname>O’donovan</surname><given-names>M.C.</given-names></name><name><surname>Peters</surname><given-names>T.J.</given-names></name></person-group><article-title>Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial</article-title><source>Br. J. Psychiatry</source><volume>198</volume><year>2011</year><fpage>464</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">21263010</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal" id="sbref27"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>G.</given-names></name><name><surname>Pelosi</surname><given-names>A.J.</given-names></name><name><surname>Araya</surname><given-names>R.</given-names></name><name><surname>Dunn</surname><given-names>G.</given-names></name></person-group><article-title>Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers</article-title><source>Psychol. Med.</source><volume>22</volume><year>1992</year><fpage>465</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">1615114</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal" id="sbref28"><person-group person-group-type="author"><name><surname>Papakostas</surname><given-names>G.I.</given-names></name><name><surname>Mcgrath</surname><given-names>P.</given-names></name><name><surname>Stewart</surname><given-names>J.</given-names></name><name><surname>Charles</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Mischoulon</surname><given-names>D.</given-names></name><name><surname>Dording</surname><given-names>C.</given-names></name><name><surname>Fava</surname><given-names>M.</given-names></name></person-group><article-title>Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder</article-title><source>Psychiatry Res.</source><volume>161</volume><year>2008</year><fpage>116</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">18755514</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal" id="sbref29"><person-group person-group-type="author"><name><surname>Papakostas</surname><given-names>G.I.</given-names></name><name><surname>Petersen</surname><given-names>T.</given-names></name><name><surname>Denninger</surname><given-names>J.</given-names></name><name><surname>Sonawalla</surname><given-names>S.B.</given-names></name><name><surname>MAHAL</surname><given-names>Y.</given-names></name><name><surname>Alpert</surname><given-names>J.E.</given-names></name><name><surname>Nierenberg</surname><given-names>A.A.</given-names></name><name><surname>Fava</surname><given-names>M.</given-names></name></person-group><article-title>Somatic symptoms in treatment-resistant depression</article-title><source>Psychiatry Res.</source><volume>118</volume><year>2003</year><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">12759160</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal" id="sbref30"><person-group person-group-type="author"><name><surname>Papakostas</surname><given-names>G.I.</given-names></name><name><surname>Petersen</surname><given-names>T.</given-names></name><name><surname>Hughes</surname><given-names>M.E.</given-names></name><name><surname>Nierenberg</surname><given-names>A.A.</given-names></name><name><surname>Alpert</surname><given-names>J.E.</given-names></name><name><surname>Fava</surname><given-names>M.</given-names></name></person-group><article-title>Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder</article-title><source>Psychiatry Res.</source><volume>126</volume><year>2004</year><fpage>287</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">15157754</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal" id="sbref31"><person-group person-group-type="author"><name><surname>Raison</surname><given-names>C.L.</given-names></name><name><surname>Capuron</surname><given-names>L.</given-names></name><name><surname>Miller</surname><given-names>A.H.</given-names></name></person-group><article-title>Cytokines sing the blues: inflammation and the pathogenesis of depression</article-title><source>Trends Immunol.</source><volume>27</volume><year>2006</year><fpage>24</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">16316783</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal" id="sbref32"><person-group person-group-type="author"><name><surname>Ressler</surname><given-names>K.J.</given-names></name><name><surname>Nemeroff</surname><given-names>C.B.</given-names></name></person-group><article-title>Role of norepinephrine in the pathophysiology and treatment of mood disorders</article-title><source>Biol. Psychiatry</source><volume>46</volume><year>1999</year><fpage>1219</fpage><lpage>1233</lpage><pub-id pub-id-type="pmid">10560027</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal" id="sbref33"><person-group person-group-type="author"><name><surname>Rush</surname><given-names>A.J.</given-names></name><name><surname>Wisniewski</surname><given-names>S.R.</given-names></name><name><surname>Warden</surname><given-names>D.</given-names></name><name><surname>Luther</surname><given-names>J.F.</given-names></name><name><surname>Davis</surname><given-names>L.L.</given-names></name><name><surname>Fava</surname><given-names>M.</given-names></name><name><surname>Nierenberg</surname><given-names>A.A.</given-names></name><name><surname>Trivedi</surname><given-names>M.H.</given-names></name></person-group><article-title>Selecting among second-step antidepressant medication monotherapies</article-title><source>Arch. Gen. Psychiatry</source><volume>65</volume><year>2008</year><fpage>870</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">18678792</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal" id="sbref34"><person-group person-group-type="author"><name><surname>Saunders</surname><given-names>J.B.</given-names></name><name><surname>Aasland</surname><given-names>O.G.</given-names></name><name><surname>Babor</surname><given-names>T.F.</given-names></name><name><surname>Delafuente</surname><given-names>J.R.</given-names></name><name><surname>Grant</surname><given-names>M.</given-names></name></person-group><article-title>Development of the alcohol-use disorders identification test (audit) – who collaborative project on early detection of persons with harmful alcohol-consumption. 2</article-title><source>Addiction</source><volume>88</volume><year>1993</year><fpage>791</fpage><lpage>804</lpage><pub-id pub-id-type="pmid">8329970</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal" id="sbref35"><person-group person-group-type="author"><name><surname>Sherbourne</surname><given-names>C.D.</given-names></name><name><surname>Stewart</surname><given-names>A.L.</given-names></name></person-group><article-title>The mos social support survey</article-title><source>Social Sci. Med.</source><volume>32</volume><year>1991</year><fpage>705</fpage><lpage>714</lpage></element-citation></ref><ref id="bib38"><element-citation publication-type="journal" id="sbref36"><person-group person-group-type="author"><name><surname>Silverstein</surname><given-names>B.</given-names></name><name><surname>Patel</surname><given-names>P.</given-names></name></person-group><article-title>Poor response to antidepressant medication of patients with depression accompanied by somatic symptomatology in the STARD Study</article-title><source>Psychiatry Res.</source><volume>87</volume><year>2011</year><fpage>121</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">21216475</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal" id="sbref37"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>G.E.</given-names></name><name><surname>Perlis</surname><given-names>R.H.</given-names></name></person-group><article-title>Personalized medicine for depression: can we match patients with treatments?</article-title><source>Am. J. Psychiatry</source><volume>167</volume><year>2010</year><fpage>1445</fpage><lpage>1455</lpage><pub-id pub-id-type="pmid">20843873</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal" id="sbref38"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>L.</given-names></name><name><surname>Mulligan</surname><given-names>J.</given-names></name><name><surname>Mason</surname><given-names>V.</given-names></name><name><surname>Tallon</surname><given-names>D.</given-names></name><name><surname>Wiles</surname><given-names>N.</given-names></name><name><surname>Cowen</surname><given-names>P.</given-names></name><name><surname>Nutt</surname><given-names>D.</given-names></name><name><surname>O’donovan</surname><given-names>M.</given-names></name><name><surname>Sharp</surname><given-names>D.</given-names></name><name><surname>Peters</surname><given-names>T.</given-names></name><name><surname>Lewis</surname><given-names>G.</given-names></name></person-group><article-title>GENetic and clinical predictors of treatment response in depression: the GenPod randomised trial protocol</article-title><source>Trials</source><volume>9</volume><year>2008</year><fpage>29</fpage><pub-id pub-id-type="pmid">18498636</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal" id="sbref39"><person-group person-group-type="author"><name><surname>Trivedi</surname><given-names>M.H.</given-names></name><name><surname>Rush</surname><given-names>A.J.</given-names></name><name><surname>Wisniewski</surname><given-names>S.R.</given-names></name><name><surname>Nierenberg</surname><given-names>A.A.</given-names></name><name><surname>Warden</surname><given-names>D.</given-names></name><name><surname>Ritz</surname><given-names>L.</given-names></name><name><surname>Norquist</surname><given-names>G.</given-names></name><name><surname>Howland</surname><given-names>R.H.</given-names></name><name><surname>Lebowitz</surname><given-names>B.</given-names></name><name><surname>Mcgrath</surname><given-names>P.J.</given-names></name><name><surname>Shores-Wilson</surname><given-names>K.</given-names></name><name><surname>Biggs</surname><given-names>M.M.</given-names></name><name><surname>Balasubramani</surname><given-names>G.K.</given-names></name><name><surname>Fava</surname><given-names>M.</given-names></name><name><surname>Team</surname><given-names>S.S.</given-names></name></person-group><article-title>Evaluation of outcomes with citalopram for depression using measurement-based care in STARD: Implications for clinical practice</article-title><source>Am. J. Psychiatry</source><volume>163</volume><year>2006</year><fpage>28</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">16390886</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal" id="sbref40"><person-group person-group-type="author"><name><surname>Trusheim</surname><given-names>M.R.</given-names></name><name><surname>Berndt</surname><given-names>E.R.</given-names></name><name><surname>Douglas</surname><given-names>F.L.</given-names></name></person-group><article-title>Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers</article-title><source>Nat. Rev. Drug Discov.</source><volume>6</volume><year>2007</year><fpage>287</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">17380152</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal" id="sbref41"><person-group person-group-type="author"><name><surname>Vanderkooy</surname><given-names>J.D.</given-names></name><name><surname>Kennedy</surname><given-names>S.H.</given-names></name><name><surname>Bagby</surname><given-names>R.M.</given-names></name></person-group><article-title>Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine</article-title><source>Can. J. Psychiatry. Revue canadienne de psychiatr.</source><volume>47</volume><year>2002</year><fpage>174</fpage><lpage>180</lpage></element-citation></ref><ref id="bib44"><element-citation publication-type="journal" id="sbref42"><person-group person-group-type="author"><name><surname>Widmer</surname><given-names>R.B.</given-names></name><name><surname>Cadoret</surname><given-names>R.J.</given-names></name></person-group><article-title>Depression in primary care: changes in pattern of patient visits and complaints during a developing depression</article-title><source>J. Fam. Pract.</source><volume>7</volume><year>1978</year><fpage>293</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">681897</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal" id="sbref43"><person-group person-group-type="author"><name><surname>Wiles</surname><given-names>N.J.</given-names></name><name><surname>Mulligan</surname><given-names>J.</given-names></name><name><surname>Peters</surname><given-names>T.J.</given-names></name><name><surname>Cowen</surname><given-names>P.J.</given-names></name><name><surname>Mason</surname><given-names>V.</given-names></name><name><surname>Nutt</surname><given-names>D.</given-names></name><name><surname>Sharp</surname><given-names>D.</given-names></name><name><surname>Tallon</surname><given-names>D.</given-names></name><name><surname>Thomas</surname><given-names>L.</given-names></name><name><surname>O’donovan</surname><given-names>M.C.</given-names></name><name><surname>Lewis</surname><given-names>G.</given-names></name></person-group><article-title>Severity of depression and response to antidepressants: GENPOD randomised controlled trial</article-title><source>Br. J. Psychiatry</source><volume>200</volume><year>2012</year><fpage>130</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">22194183</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal" id="sbref44"><person-group person-group-type="author"><name><surname>Zigmond</surname><given-names>A.S.</given-names></name><name><surname>Snaith</surname><given-names>R.P.</given-names></name></person-group><article-title>The hospital anxiety and depression scale</article-title><source>Acta Psychiatr. Scand.</source><volume>67</volume><year>1983</year><fpage>361</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">6880820</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal" id="sbref45"><person-group person-group-type="author"><name><surname>Zimmerman</surname><given-names>M.</given-names></name><name><surname>Posternak</surname><given-names>M.</given-names></name><name><surname>Friedman</surname><given-names>M.</given-names></name><name><surname>Attiullah</surname><given-names>N.</given-names></name><name><surname>Baymiller</surname><given-names>S.</given-names></name><name><surname>Boland</surname><given-names>R.</given-names></name><name><surname>Berlowitz</surname><given-names>S.</given-names></name><name><surname>Rahman</surname><given-names>S.</given-names></name><name><surname>UY</surname><given-names>K.</given-names></name><name><surname>Singer</surname><given-names>S.</given-names></name></person-group><article-title>Which factors influence psychiatrists’ selection of antidepressants?</article-title><source>Am. J. Psychiatry</source><volume>161</volume><year>2004</year><fpage>1285</fpage><lpage>1289</lpage><pub-id pub-id-type="pmid">15229063</pub-id></element-citation></ref></ref-list><sec id="s0100" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary material</title><p>Supplementary data associated with this article can be found in the online version at <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jad.2014.03.051" id="ir0005">doi:10.1016/j.jad.2014.03.051</ext-link>.</p></sec><sec id="s0105" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary materials</title><p><supplementary-material content-type="local-data" id="ec0005"><caption><p>Supplementary Data</p></caption><media xlink:href="mmc1.pdf"></media></supplementary-material></p></sec><ack id="ack0005"><title>Acknowledgements</title><p>The original GenPod trial was supported by the Mental Health Research Network. We are grateful for the support of the patients who agreed to participate and their general practitioners. We would especially like to acknowledge a number of our colleagues who have been involved with the study and who have provided a valuable contribution but who have not participated in drafting this manuscript; Deborah Sharp, Debbie Tallon, Phil Cowan, Jean Mulligan, Victoria Mason, Laura Thomas, Michael O’Donovan and Helen Bould.</p></ack></back><floats-group><fig id="f0005"><label>Fig. 1</label><caption><p>Distribution of physical symptoms present for 4–7 days/week.</p></caption><graphic xlink:href="gr1"></graphic></fig><fig id="f0010"><label>Fig. 2</label><caption><p>BDI-II scores at baseline, 6 and 12 weeks stratified by physical symptom group.</p></caption><graphic xlink:href="gr2"></graphic></fig><table-wrap id="t0005" position="float"><label>Table 1</label><caption><p>Characteristics of participants, according to baseline physical symptoms.</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th><bold>Overall (</bold><italic><bold>N</bold></italic><bold>=601)</bold></th><th><bold>None (</bold><italic><bold>N</bold></italic><bold>=161)</bold></th><th><bold>Few (</bold><italic>N</italic>=<bold>126)</bold></th><th><bold>Several (</bold><italic><bold>N</bold></italic><bold>=156)</bold></th><th><bold>Multiple (</bold><italic><bold>N</bold></italic><bold>=158)</bold></th></tr></thead><tbody><tr><td><bold>Mean age (SD)</bold></td><td>38.82 (12.35)</td><td>38.16 (11.05)</td><td>39.88 (12.65)</td><td>38.21 (12.31)</td><td>39.27 (13.40)</td></tr><tr><td><bold>N (%) female</bold></td><td>408 (67.87)</td><td>98 (60.87)</td><td>77 (61.11)</td><td>119 (76.28)</td><td>114 (72.15)</td></tr><tr><td><bold>N (%) CIS-R &gt;=28</bold></td><td>394 (65.56)</td><td>73 (45.34)</td><td>75 (59.52)</td><td>105 (67.31)</td><td>141 (89.24)</td></tr><tr><td><bold>Mean BDI tot (SD)</bold></td><td>33.67 (9.70)</td><td>29.67 (8.37)</td><td>32.68 (8.70)</td><td>34.27 (9.33)</td><td>37.94 (10.17)</td></tr><tr><td><bold>Mean life events score (SD)</bold></td><td>1.67 (1.30)</td><td>1.44 (1.27)</td><td>1.42 (1.16)</td><td>1.81 (1.42)</td><td>2.00 (1.48)</td></tr><tr><td><bold>Mean social support score (SD)</bold></td><td>12.02 (3.80)</td><td>12.51 (3.50)</td><td>11.80 (3.99)</td><td>11.74 (3.77)</td><td>11.96 (3.94)</td></tr><tr><td><bold>N (%) taking citalopram</bold></td><td>298 (49.60)</td><td>81 (50.31)</td><td>58 (46.03)</td><td>84 (53.85)</td><td>75 (47.47)</td></tr><tr><td><bold>N (%) in full time work</bold></td><td>243 (40.43)</td><td>70 (43.48)</td><td>55 (43.65)</td><td>56 (35.90)</td><td>62 (39.24)</td></tr><tr><td><bold>N (%) with no previous depression</bold></td><td>167 (27.80)</td><td>49 (30.63)</td><td>33 (26.19)</td><td>42 (26.93)</td><td>41 (25.95)</td></tr><tr><td><bold>Mean anxiety symptoms on CIS-R (SD)</bold></td><td>2.49 (1.47)</td><td>2.11 (1.50)</td><td>2.24 (1.32)</td><td>2.37 (1.51)</td><td>2.94 (1.41)</td></tr><tr><td><bold>Mean AUDIT score (alcohol use) (SD)</bold></td><td>4.01 (3.70)</td><td>4.09 (3.04)</td><td>4.00 (3.89)</td><td>4.19 (3.88)</td><td>3.76 (3.85)</td></tr><tr><td><bold>N (%) chronic illness</bold></td><td>288 (47.92)</td><td>64 (39.75)</td><td>53 (42.06)</td><td>81 (51.92)</td><td>90 (56.96)</td></tr><tr><td><bold>Mean HAD anxiety score (SD)</bold></td><td>13.22 (3.57)</td><td>12.06 (3.42)</td><td>12.59 (3.37)</td><td>13.19 (3.65)</td><td>14.95 (3.12)</td></tr><tr><td><bold>Mean HAD depression score (SD)</bold></td><td>12.6 (4.00)</td><td>11.55 (3.76)</td><td>12.12 (3.71)</td><td>12.49 (4.02)</td><td>14.16 (4.00)</td></tr><tr><td><bold>Number of Caucasians (%)</bold></td><td>575 (95.67)</td><td>158 (98.14)</td><td>115 (91.27)</td><td>152 (97.44)</td><td>150 (94.94)</td></tr></tbody></table><table-wrap-foot><fn><p>SD (standard deviation), BDI (Beck Depression Inventory), CIS-R (Clinical Interview Schedule-Revised), HAD (Hospital Anxiety and Depression scale).</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0010" position="float"><label>Table 2</label><caption><p>Differences in BDI-II score between no physical symptoms and few, several and multiple physical symptoms at 6 and 12 weeks for all treatments.</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th><bold>None (</bold><italic><bold>N</bold></italic><bold>=161)</bold></th><th><bold>Few (</bold><italic><bold>N</bold></italic>=<bold>126)</bold></th><th><bold>Several (</bold><italic><bold>N</bold></italic><bold>=156)</bold></th><th><bold>Multiple (</bold><italic><bold>N</bold></italic><bold>=158)</bold></th></tr></thead><tbody><tr><td><bold>Data at 6 weeks</bold></td><td></td><td align="char"></td><td align="char"></td><td align="char"></td></tr><tr><td>Unadjusted difference in BDI score at 6 weeks<xref rid="tbl2fna" ref-type="table-fn">a</xref></td><td>reference</td><td>1.35 (−1.28, 3.98)</td><td align="char">1.31 (−1.23, 3.84)</td><td align="char">4.50 (1.87, 7.14)</td></tr><tr><td>Adjusted difference in BDI score at 6 weeks<xref rid="tbl2fnb" ref-type="table-fn">b</xref></td><td></td><td>0.53 (−1.97, 3.03)</td><td align="char">−0.19 (−2.61, 2.24)</td><td align="char">2.17 (−0.39, 4.73)</td></tr><tr><td>Adjusted for history of depression</td><td></td><td>1.32 (−1.32, 3.95)</td><td align="char">1.25 (−1.29, 3.79)</td><td align="char">4.46 (1.82, 7.10)</td></tr><tr><td>Adjusted for gender</td><td></td><td>1.28 (−1.34, 3.90)</td><td align="char">0.96 (−1.59, 3.52)</td><td align="char">4.16 (1.50, 6.82)</td></tr><tr><td>Adjust for life events</td><td></td><td>1.36 (−1.28, 3.99)</td><td align="char">1.24 (−1.31, 3.78)</td><td align="char">4.40 (1.74, 7.06)</td></tr><tr><td>Adjust for chronic illness</td><td></td><td>1.36 (−1.26, 3.97)</td><td align="char">1.23 (−1.30, 3.97)</td><td align="char">4.16 (1.52, 6.81)</td></tr><tr><td>Adjusted for social support</td><td></td><td>1.10 (−1.49, 3.68)</td><td align="char">0.94 (−1.55, 3.44)</td><td align="char">4.33 (1.74, 6.92)</td></tr><tr><td>Adjusted for HAD- anxiety</td><td></td><td>1.36 (−1.24, 3.96)</td><td align="char">1.13 (−1.38, 3.63)</td><td align="char">3.64 (1.00, 6.28)</td></tr><tr><td>Adjusted for adherence at 6 weeks</td><td></td><td>1.24 (−1.37, 3.71)</td><td align="char">1.19 (−1.34, 3.71)</td><td align="char">4.47 (1.85, 7.10)</td></tr><tr><td>Adjusted for CISR anxiety</td><td></td><td>0.57 (−2.17, 3.33)</td><td align="char">1.21 (−1.49, 3.92)</td><td align="char">3.97 (1.32, 6.61)</td></tr><tr><td colspan="5">  </td></tr><tr><td><bold>Data at 12 weeks</bold></td><td></td><td></td><td align="char"></td><td align="char"></td></tr><tr><td>Unadjusted difference in BDI score at 12 weeks<xref rid="tbl2fna" ref-type="table-fn">a</xref></td><td></td><td>1.51 (−1.42, 4.44)</td><td align="char">1.86 (−0.93, 4.66)</td><td align="char">4.51 (1.60, 7.42)</td></tr><tr><td>Adjusted difference in BDI score at 12 weeks<xref rid="tbl2fnb" ref-type="table-fn">b</xref></td><td></td><td>0.78 (−2.05, 3.61)</td><td align="char">0.67 (−2.05, 3.40)</td><td align="char">2.43 (−0.46, 5.32)</td></tr><tr><td>Adjusted for history of depression</td><td></td><td>1.32 (−1.59, 4.24)</td><td align="char">1.63 (−1.16, 4.41)</td><td align="char">4.25 (1.35, 7.15)</td></tr><tr><td>Adjusted for gender</td><td></td><td>1.38 (−1.55, 4.30)</td><td align="char">1.46 (−1.36, 4.28)</td><td align="char">4.13 (1.19, 7.06)</td></tr><tr><td>Adjust for life events</td><td></td><td>1.45 (−1.46, 4.37)</td><td align="char">1.71 (−1.07, 4.50)</td><td align="char">3.99 (1.06, 6.93)</td></tr><tr><td>Adjust for chronic illness</td><td></td><td>1.56 (−1.33, 4.45)</td><td align="char">1.61 (−1.16, 4.37)</td><td align="char">3.74 (0.84, 6.65)</td></tr><tr><td>Adjusted for social support</td><td></td><td>1.30 (−1.58, 4.18)</td><td align="char">1.35 (−1.41, 4.11)</td><td align="char">4.16 (1.29, 7.04)</td></tr><tr><td>Adjusted for HAD- anxiety</td><td></td><td>1.56 (−1.34, 4.46)</td><td align="char">1.65 (−1.12, 4.42)</td><td align="char">3.70 (0.77, 6.63)</td></tr><tr><td>Adjusted for adherence at 12 weeks</td><td></td><td>1.56 (−1.37, 4.50)</td><td align="char">1.88 (−0.92, 4.68)</td><td align="char">4.58 (1.66, 7.51)</td></tr><tr><td>Adjusted for CISR anxiety 12 weeks</td><td></td><td>0.62 (−2.44, 3.69)</td><td align="char">2.23 (−0.77, 5.23)</td><td align="char">3.55 (0.61, 6.48)</td></tr></tbody></table><table-wrap-foot><fn><p>BDI (Beck Depression Inventory), CIS-R (Clinical Interview Schedule-Revised), HAD (Hospital Anxiety and Depression scale).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fna"><label>a</label><p>Adjusted for trial variables.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnb"><label>b</label><p>Adjusted for baseline BDI-II.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0015" position="float"><label>Table 3</label><caption><p>Mean BDI-II scores of the citalopram and reboxetine groups as randomised, at 6 and 12 weeks by physical symptoms group, adjusted for trial variables.</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th><bold>Overall (</bold><italic><bold>N</bold></italic><bold>=601)</bold></th><th><bold>None (</bold><italic><bold>N</bold></italic><bold>=126)</bold></th><th><bold>Few (</bold><bold><italic>N</italic>=131)</bold></th><th><bold>Several (</bold><italic><bold>N</bold></italic><bold>=148)</bold></th><th><bold>Multiple (</bold><italic><bold>N</bold></italic><bold>=196)</bold></th></tr></thead><tbody><tr><td>BDI at 6 weeks for citalopram (SD)</td><td>18.87(10.82)</td><td>16.88 (9.37)</td><td>18.13 (9.88)</td><td>17.64 (11.00)</td><td>22.89 (11.92)</td></tr><tr><td>BDI at 6 weeks for reboxetine (SD)</td><td>19.58 (11.47)</td><td>16.95 (10.05)</td><td>19.13 (10.96)</td><td>20.00 (11.11)</td><td>22.26 (11.94)</td></tr><tr><td>Adjusted difference between citalopram and reboxetine at 6 weeks (SE)</td><td>NA</td><td>1.01 (1.42)</td><td>0.75 (1.88)</td><td>3.14 (1.91)</td><td>1.11 (1.83)</td></tr><tr><td>BDI at 12 weeks for citalopram (SD)</td><td>15.38 (11.47)</td><td>13.62 (9.43)</td><td>14.58 (9.88)</td><td>13.24 (10.62)</td><td>20.29 (14.17)</td></tr><tr><td>BDI at 12 weeks for reboxetine (SD)</td><td>15.09 (11.29)</td><td>11.87 (9.12)</td><td>14.51 (9.50)</td><td>17.41(12.65)</td><td>16.50 (12.50)</td></tr><tr><td>Adjusted difference between citalopram and reboxetine at 12 weeks (SE)</td><td>NA</td><td>0.66 (1.54)</td><td>0.07 (1.88)</td><td>4.9 (2.10)</td><td>3.77 (2.23)</td></tr></tbody></table><table-wrap-foot><fn><p>BDI (Beck Depression Inventory), SD (standard deviation), SE (standard error).</p></fn></table-wrap-foot></table-wrap></floats-group></article>